$FULC
Fulcrum Therapeutics, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022002727 Filed on March 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 2020 Q4
Revenue $2.592M $19.16M $4.230M
YoY Change -45.88% 117.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.76M $30.52M $5.870M
YoY Change 95.62% 42.66% 33.41%
% of Gross Profit
Research & Development $17.83M $69.70M $16.15M
YoY Change 9.16% 18.05% 33.58%
% of Gross Profit
Depreciation & Amortization $500.0K $2.500M $730.0K
YoY Change -16.67% 4.17% 40.38%
% of Gross Profit
Operating Expenses $28.59M $100.2M $22.01M
YoY Change 30.95% 24.6% 33.47%
Operating Profit -$26.00M -$81.05M
YoY Change 52.54% 13.19%
Interest Expense $70.00K $207.0K
YoY Change 59.09% -73.86%
% of Operating Profit
Other Income/Expense, Net $70.00K $207.0K $70.00K
YoY Change 75.0% -73.8% 600.0%
Pretax Income -$25.93M -$80.85M -$17.72M
YoY Change 52.52% 14.16% 9.93%
Income Tax
% Of Pretax Income
Net Earnings -$25.93M -$80.85M -$17.72M
YoY Change 52.53% 14.16% 9.93%
Net Earnings / Revenue -1000.31% -421.89% -418.91%
Basic Earnings Per Share -$0.64 -$2.29
Diluted Earnings Per Share -$637.9K -$2.286M -$643.2K
COMMON SHARES
Basic Shares Outstanding 40.64M 35.36K
Diluted Shares Outstanding 40.64K 35.36K

Balance Sheet

Concept 2022 Q1 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $195.1M $218.2M $112.9M
YoY Change 35.59% 93.23% 16.77%
Cash & Equivalents $33.31M $35.41M $57.05M
Short-Term Investments $161.8M $182.8M $55.86M
Other Short-Term Assets $47.00K $3.726M $74.00K
YoY Change -81.78% -4.46% -73.94%
Inventory
Prepaid Expenses
Receivables $1.208M $4.110M $2.700M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $200.1M $226.0M $119.5M
YoY Change 36.1% 89.12% 19.41%
LONG-TERM ASSETS
Property, Plant & Equipment $7.888M $7.368M $8.397M
YoY Change 1.13% -12.29% -8.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $816.0K $1.634M $578.0K
YoY Change -52.0% -3.88% 879.66%
Total Long-Term Assets $20.18M $9.002M $10.07M
YoY Change 112.46% -10.87% -2.79%
TOTAL ASSETS
Total Short-Term Assets $200.1M $226.0M $119.5M
Total Long-Term Assets $20.18M $9.002M $10.07M
Total Assets $220.2M $235.0M $129.6M
YoY Change 40.73% 81.33% 17.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.003M $4.788M $4.079M
YoY Change 25.06% 16.78% 86.6%
Accrued Expenses $9.231M $9.157M $7.200M
YoY Change 77.52% 27.18% 33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $18.29M $19.20M $26.73M
YoY Change -19.08% -28.09% 120.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.80M $4.262M $7.700M
YoY Change 109.84% -44.65% 13900.0%
Total Long-Term Liabilities $12.80M $4.262M $7.700M
YoY Change 109.84% -44.65% 13900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.29M $19.20M $26.73M
Total Long-Term Liabilities $12.80M $4.262M $7.700M
Total Liabilities $31.09M $23.46M $34.40M
YoY Change 8.32% -31.8% 47.71%
SHAREHOLDERS EQUITY
Retained Earnings -$328.4M -$221.6M
YoY Change 46.96%
Common Stock $518.6M $316.8M
YoY Change 33.14%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change
Treasury Stock Shares $0.00 $0.00
Shareholders Equity $189.2M $211.5M $95.18M
YoY Change
Total Liabilities & Shareholders Equity $220.2M $235.0M $129.6M
YoY Change 40.73% 81.33% 17.33%

Cashflow Statement

Concept 2022 Q1 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$25.93M -$80.85M -$17.72M
YoY Change 52.53% 14.16% 9.93%
Depreciation, Depletion And Amortization $500.0K $2.500M $730.0K
YoY Change -16.67% 4.17% 40.38%
Cash From Operating Activities -$22.11M -$78.48M -$19.83M
YoY Change 36.24% 46.26% 341.65%
INVESTING ACTIVITIES
Capital Expenditures $246.0K $1.713M -$470.0K
YoY Change -6.11% 27.65% 370.0%
Acquisitions
YoY Change
Other Investing Activities $19.91M -$128.0M -$14.13M
YoY Change 56.98% 129.31%
Cash From Investing Activities $19.66M -$129.7M -$14.60M
YoY Change 58.35% 126.94% 14500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $348.0K $3.668M
YoY Change 274.19% 156.68%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 348.0K 186.5M 6.250M
YoY Change -99.27% 162.2% -2332.14%
NET CHANGE
Cash From Operating Activities -22.11M -78.48M -19.83M
Cash From Investing Activities 19.66M -129.7M -14.60M
Cash From Financing Activities 348.0K 186.5M 6.250M
Net Change In Cash -2.099M -21.64M -28.18M
YoY Change -104.8% -45.44% 478.64%
FREE CASH FLOW
Cash From Operating Activities -$22.11M -$78.48M -$19.83M
Capital Expenditures $246.0K $1.713M -$470.0K
Free Cash Flow -$22.35M -$80.19M -$19.36M
YoY Change 35.57% 45.81% 341.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Open Tax Year
OpenTaxYear
2016 2017 2018 2019 2020
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001680581
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Entity File Number
EntityFileNumber
001-38978
CY2021 dei Entity Registrant Name
EntityRegistrantName
FULCRUM THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4839948
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
26 Landsdowne Street
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Local Phone Number
LocalPhoneNumber
651-8851
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
2000000
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1137000
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35412000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57052000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
182750000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
55862000
CY2021 dei Trading Symbol
TradingSymbol
FULC
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
2500000
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
248910889
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40637216
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2020Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
531000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4199000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4065000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
225998000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
119510000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7368000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8397000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1092000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1092000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
542000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
578000
CY2021Q4 us-gaap Assets
Assets
235000000
CY2020Q4 us-gaap Assets
Assets
129577000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4788000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4079000
CY2021Q4 fulc Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
9231000
CY2020Q4 fulc Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
7267000
CY2021Q4 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
469000
CY2020Q4 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
469000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4711000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14910000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19199000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26725000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1680000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28067402
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40626224
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27941566
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
514362000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1649000
CY2021Q4 fulc Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
2582000
CY2020Q4 fulc Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
3051000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2971000
CY2021Q4 us-gaap Liabilities
Liabilities
23461000
CY2020Q4 us-gaap Liabilities
Liabilities
34396000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40636398
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
316775000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-397000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302467000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221620000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
211539000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
95181000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235000000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129577000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19163000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8823000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69701000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59042000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30516000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21392000
CY2021 us-gaap Operating Expenses
OperatingExpenses
100217000
CY2020 us-gaap Operating Expenses
OperatingExpenses
80434000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-81054000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-71611000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
207000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
792000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-80847000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-70819000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.29
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.79
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35361
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25354
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-80847000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-70819000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-395000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-395000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81242000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70821000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
87153000
CY2020 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1430000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
15000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7350000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-70819000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
95181000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
182857000
CY2021 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
3668000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
5000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11070000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-395000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-80847000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
211539000
CY2021 us-gaap Profit Loss
ProfitLoss
-80847000
CY2020 us-gaap Profit Loss
ProfitLoss
-70819000
CY2021 us-gaap Depreciation
Depreciation
2515000
CY2020 us-gaap Depreciation
Depreciation
2379000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
11070000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7350000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-673000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7881000
CY2021 fulc Increase Decrease In Deferred Rent And Deferred Lease Incentive
IncreaseDecreaseInDeferredRentAndDeferredLeaseIncentive
-438000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
68000
CY2021 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
500000
CY2020 fulc Increase Decrease In Deferred Rent And Deferred Lease Incentive
IncreaseDecreaseInDeferredRentAndDeferredLeaseIncentive
-380000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78478000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53655000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
216234000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
124270000
CY2021 fulc Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
88278000
CY2020 fulc Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
68474000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1713000
CY2020 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
2000000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
606000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-531000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
134000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
697000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-36000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
519000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
973000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1773000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1950000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1976000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-13170000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1342000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-129669000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57138000
CY2021 us-gaap Proceeds From Repurchase Of Redeemable Preferred Stock
ProceedsFromRepurchaseOfRedeemablePreferredStock
0
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
-193000
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
64210000
CY2021 fulc Net Proceeds From Issuances Of Common Stock In Public Offerings
NetProceedsFromIssuancesOfCommonStockInPublicOfferings
0
CY2020 fulc Net Proceeds From Issuances Of Common Stock In Public Offerings
NetProceedsFromIssuancesOfCommonStockInPublicOfferings
5736000
CY2021 fulc Proceeds From Issuance Of Common Stock In Connection With Public Offerings Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockInConnectionWithPublicOfferingsNetOfIssuanceCosts
182857
CY2020 fulc Proceeds From Issuance Of Common Stock In Connection With Public Offerings Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockInConnectionWithPublicOfferingsNetOfIssuanceCosts
0
CY2021 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
18000
CY2020 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
50000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3668000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1429000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
186507000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71132000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21640000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39661000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58144000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97805000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36504000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58144000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 us-gaap Interest Paid Net
InterestPaidNet
4000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
37000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
262000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35412000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57052000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1092000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1092000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36504000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58144000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4600000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
11.00
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
47400000
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7590000
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
19.00
CY2021Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
135500000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302500000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amount of expenses during the reported periods. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ from those estimates or assumptions.</span>
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2021Q4 fulc Fair Value Transfers Between Levels
FairValueTransfersBetweenLevels
0
CY2020Q4 fulc Fair Value Transfers Between Levels
FairValueTransfersBetweenLevels
0
CY2021Q4 fulc Cash And Cash Equivalents Amortized Cost
CashAndCashEquivalentsAmortizedCost
35412000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
35412000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
183147000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
397000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
182750000
CY2021Q4 fulc Cash Equivalents And Marketable Securities Amortized Cost Basis
CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis
218559000
CY2021Q4 fulc Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Gains Before Tax
CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax
0
CY2021Q4 fulc Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
397000
CY2021Q4 fulc Cash Equivalents And Marketable Securities Fair Value Disclosure
CashEquivalentsAndMarketableSecuritiesFairValueDisclosure
218162000
CY2020Q4 fulc Cash And Cash Equivalents Amortized Cost
CashAndCashEquivalentsAmortizedCost
57052000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
57052000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55864000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
55862000
CY2020Q4 fulc Cash Equivalents And Marketable Securities Amortized Cost Basis
CashEquivalentsAndMarketableSecuritiesAmortizedCostBasis
112916000
CY2020Q4 fulc Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Gains Before Tax
CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedGainsBeforeTax
2000
CY2020Q4 fulc Cash Equivalents And Marketable Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndMarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2020Q4 fulc Cash Equivalents And Marketable Securities Fair Value Disclosure
CashEquivalentsAndMarketableSecuritiesFairValueDisclosure
112914000
CY2021 fulc Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
180800000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2021Q4 fulc Aggregate Fair Value Of Securities Remaining Contractual Maturity Of Greater Than One Year
AggregateFairValueOfSecuritiesRemainingContractualMaturityOfGreaterThanOneYear
39700000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15637000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14515000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8269000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6118000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7368000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8397000
CY2021 us-gaap Depreciation
Depreciation
2500000
CY2020 us-gaap Depreciation
Depreciation
2400000
CY2021Q4 fulc Prepaid Expenses
PrepaidExpenses
3400000
CY2020Q4 fulc Prepaid Expenses
PrepaidExpenses
3668000
CY2021Q4 fulc Prepaid Sign On Bonuses Subject To Vesting Provisions
PrepaidSignOnBonusesSubjectToVestingProvisions
326000
CY2020Q4 fulc Prepaid Sign On Bonuses Subject To Vesting Provisions
PrepaidSignOnBonusesSubjectToVestingProvisions
147000
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
473000
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
176000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
0
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
74000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4199000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4065000
CY2021Q4 fulc Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3171000
CY2020Q4 fulc Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
4082000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4990000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2928000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
996000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
196000
CY2021Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0
CY2020Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
17000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
74000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44000
CY2021Q4 fulc Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
9231000
CY2020Q4 fulc Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
7267000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders
CY2021Q4 fulc Number Of Common Stock Voting Rights
NumberOfCommonStockVotingRights
1
us-gaap Dividends
Dividends
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 fulc Shares Reserved For Conversion Of Preferred Stock And Future Issuance Of Common Stock
SharesReservedForConversionOfPreferredStockAndFutureIssuanceOfCommonStock
6181336
CY2020Q4 fulc Shares Reserved For Conversion Of Preferred Stock And Future Issuance Of Common Stock
SharesReservedForConversionOfPreferredStockAndFutureIssuanceOfCommonStock
5156962
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
11070000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7350000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
34600000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M3D
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67043000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2424000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2497000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2572000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2649000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2729000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4237000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17108000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0031
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0079
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0239
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0257
CY2021 fulc Effective Income Tax Rate Reconciliation Federal Orphan Drug Credits
EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits
0.0451
CY2020 fulc Effective Income Tax Rate Reconciliation Federal Orphan Drug Credits
EffectiveIncomeTaxRateReconciliationFederalOrphanDrugCredits
0.0428
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0612
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0614
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.0006
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0047
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3365
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3367
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
46603000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8774000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6842000
CY2021Q4 fulc Deferred Tax Assets Orphan Drug Credit Carryforwards
DeferredTaxAssetsOrphanDrugCreditCarryforwards
6679000
CY2020Q4 fulc Deferred Tax Assets Orphan Drug Credit Carryforwards
DeferredTaxAssetsOrphanDrugCreditCarryforwards
3032000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
6192000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
6722000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1061000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1791000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
4537000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2240000
CY2021Q4 fulc Deferred Tax Assets Lease Incentive
DeferredTaxAssetsLeaseIncentive
832000
CY2020Q4 fulc Deferred Tax Assets Lease Incentive
DeferredTaxAssetsLeaseIncentive
962000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
471000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
450000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95589000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
68642000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
94630000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67427000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
959000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1215000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
959000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1215000
CY2021Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
27200000
CY2021Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 fulc Defined Contribution Plan Name
DefinedContributionPlanName
401(k)
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5198528
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3088183

Files In Submission

Name View Source Status
0000950170-22-002727-index-headers.html Edgar Link pending
0000950170-22-002727-index.html Edgar Link pending
0000950170-22-002727.txt Edgar Link pending
0000950170-22-002727-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fulc-20211231.htm Edgar Link pending
fulc-20211231.xsd Edgar Link pending
fulc-20211231_cal.xml Edgar Link unprocessable
fulc-20211231_def.xml Edgar Link unprocessable
fulc-20211231_htm.xml Edgar Link completed
fulc-20211231_lab.xml Edgar Link unprocessable
fulc-20211231_pre.xml Edgar Link unprocessable
fulc-ex10_10.htm Edgar Link pending
fulc-ex10_12.htm Edgar Link pending
fulc-ex10_13.htm Edgar Link pending
fulc-ex10_14.htm Edgar Link pending
fulc-ex10_15.htm Edgar Link pending
fulc-ex10_23.htm Edgar Link pending
fulc-ex21_1.htm Edgar Link pending
fulc-ex23_1.htm Edgar Link pending
fulc-ex31_1.htm Edgar Link pending
fulc-ex31_2.htm Edgar Link pending
fulc-ex32_1.htm Edgar Link pending
fulc-ex32_2.htm Edgar Link pending
img43028003_0.jpg Edgar Link pending
img43028003_1.jpg Edgar Link pending
img43028003_10.jpg Edgar Link pending
img43028003_11.jpg Edgar Link pending
img43028003_12.jpg Edgar Link pending
img43028003_2.jpg Edgar Link pending
img43028003_3.jpg Edgar Link pending
img43028003_4.jpg Edgar Link pending
img43028003_5.jpg Edgar Link pending
img43028003_6.jpg Edgar Link pending
img43028003_7.jpg Edgar Link pending
img43028003_8.jpg Edgar Link pending
img43028003_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending